We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

ORTHO CLINICAL DIAGNOSTICS

Ortho Clinical Diagnostics is a global provider of in vitro diagnostics, including testing platforms and clinical ass... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Ortho’s Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 12 Jul 2021
Print article
Illustration
Illustration
Ortho Clinical Diagnostics’ (Raritan, NJ, USA) VITROS Anti-SARS-CoV-2 IgG Quantitative Test has become the first quantitative COVID-19 IgG antibody test to receive US Food and Drug Administration (FDA) Emergency Use Authorization (EUA).

Ortho’s new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2. The test offers 100% specificity and excellent sensitivity. The new test is calibrated to the World Health Organization (WHO) International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2. This uniform data is a first step toward understanding the rise and fall of antibodies in individuals and the long-term impacts of the COVID-19 pandemic on communities and the overall population. With the FDA EUA, Ortho is now the only company that offers laboratories in the US a quantitative IgG test to the spike protein in addition to a total antibody test to the nucleocapsid protein.

“The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho’s leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used,” said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics. “Ortho’s quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2.”


Gold Supplier
SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG
New
SARS-CoV-2 IgM ELISA
SARS-CoV-2 IgM ELISA
New
SARS-CoV-2 Detection Kit
Loopamp SARS-CoV-2 Detection Kit
New
Laboratory Automation System
autioclart

Print article

Channels

Molecular Diagnostics

view channel
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)

Highly Sensitive Genetic Test for Glaucoma Developed

In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.